STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program

🇺🇸 STAT News Health (US) —
STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program

AI Summary

Eli Lilly’s retatrutide has been provided to a single individual under a compassionate use program, highlighting the potential of this 'triple-G' weight loss drug. This update comes amid other significant biotech news including Pfizer’s lung cancer trial results.

The "triple-G" weight loss drug, Pfizer's lung cancer trial results, and more biotech news from The Readout

Health retatrutide compassionate use weight loss biotech Pfizer lung cancer

Read original source →